Check Cap Ltd (CHEK) Given Average Recommendation of “Buy” by Brokerages

Shares of Check Cap Ltd (NASDAQ:CHEK) have been assigned a consensus broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.

Brokerages have set a 1-year consensus price target of $10.50 for the company and are predicting that the company will post ($0.47) earnings per share for the current quarter, according to Zacks. Zacks has also given Check Cap an industry rank of 102 out of 256 based on the ratings given to its competitors.

A number of equities research analysts have issued reports on CHEK shares. Dougherty & Co started coverage on shares of Check Cap in a research note on Tuesday, February 5th. They set a “buy” rating and a $6.00 price objective on the stock. Zacks Investment Research upgraded shares of Check Cap from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a research note on Monday, March 4th.

NASDAQ:CHEK traded down $0.13 during mid-day trading on Monday, reaching $2.18. 83,545 shares of the company’s stock were exchanged, compared to its average volume of 280,282. Check Cap has a one year low of $1.62 and a one year high of $5.43. The firm has a market cap of $3.50 million and a price-to-earnings ratio of -0.84.

Check Cap (NASDAQ:CHEK) last announced its quarterly earnings data on Thursday, March 28th. The medical research company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.04). As a group, analysts anticipate that Check Cap will post -1.7 EPS for the current fiscal year.

A hedge fund recently raised its stake in Check Cap stock. Wells Fargo & Company MN boosted its position in shares of Check Cap Ltd (NASDAQ:CHEK) by 96.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,800 shares of the medical research company’s stock after buying an additional 4,800 shares during the period. Wells Fargo & Company MN owned approximately 0.61% of Check Cap worth $26,000 at the end of the most recent quarter.

About Check Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Read More: What is a resistance level?

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.